# Progress in treatment of primary mediastinal large B-cell lymphoma

## TL;DR

Primary mediastinal large B-cell lymphoma is an aggressive cancer affecting young women, with treatment strategies still being refined.

## Contribution

The paper reviews current treatment approaches and highlights the potential of novel therapies for this specific lymphoma subtype.

## Key findings

- PMBCL typically affects young women and presents as a large mediastinal mass.
- No standard PMBCL prognosis system exists, and optimal treatment remains unclear.
- New therapies like PD-1 inhibitors and CAR-T cells show promise for poor-prognosis patients.

## Abstract

原发纵隔大B细胞淋巴瘤（PMBCL）是一种起源于胸腺的侵袭性B细胞淋巴瘤。具有不同于非特指型弥漫大B细胞淋巴瘤的临床和生物学特征，PMBCL好发于年轻女性，通常表现为前纵隔巨大肿块，大多数患者就诊时处于Ⅰ～Ⅱ期，目前尚无标准的PMBCL预后评分系统。PMBCL治疗多采用免疫化疗，但最佳一线治疗方案尚无定论，并且放疗的地位存在争议，PET-CT指导治疗的价值有待进一步证实。复发/难治PMBCL预后较差，PD-1抑制剂、维布妥昔单抗和CAR-T细胞等新型疗法有助于改善此类患者生存。